ロード中...
Combination treatment using DDX3 and PARP inhibitors induces synthetic lethality in BRCA1-proficient breast cancer
Triple-negative breast cancers have unfavorable outcomes due to their inherent aggressive behavior and lack of targeted therapies. Breast cancers occurring in BRCA1 mutation carriers are mostly triple-negative and harbor homologous recombination deficiency, sensitizing them to inhibition of a second...
保存先:
| 出版年: | Med Oncol |
|---|---|
| 主要な著者: | , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5576028/ https://ncbi.nlm.nih.gov/pubmed/28138868 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12032-017-0889-2 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|